Elastography Australia vs FibroScan
See why clinicians are choosing guided liver elastography over traditional blind point-and-shoot devices. The difference is clear.
FibroScan comparisons on this page refer to commonly deployed standard models (for example 502 Touch, 530 Compact). The FibroScan 630 Expert includes ultrasound localization and additional outputs.
Elastography Australia
Guided Elastography
- 2D Ultrasound Imaging
- ~96.5% Success (NAFLD cohort)
- ~$45,000 AUD
- Single Universal Probe
FibroScan
Standard TE (typical install)
- No Imaging Guidance
- ~85% Success Rate
- ~$90,000+ AUD
- Multiple Probes Required
Guided vs Blind: The Core Difference
Understanding why imaging guidance matters for accurate liver assessment.
Elastography Australia (Guided)
Recommended- Real-time 2D ultrasound imaging shows exact probe position
- Operator can see liver parenchyma and avoid vessels
- Visual confirmation of measurement location
- Immediate feedback on positioning quality
- Reduced operator dependency
FibroScan (standard TE units)
Traditional- Most installed systems (e.g. 502/530) have no B-mode for targeting
- Cannot visualize liver parenchyma during acquisition on those models
- Relies on external landmarks and operator skill
- 630 Expert adds ultrasound localization—not the same as full guided SWE
- XL probe mitigates some high-BMI limits of the M probe
Feature by Feature
Detailed Comparison
Accuracy & Reliability
Real-time visualization
No B-mode; 630 Expert adds ultrasound localization
Large published NAFLD FibroTouch cohort
Depends on probe, operator, patient
See published studies
XL probe improves vs M in obesity
Quality threshold
Quality threshold
See structures in real-time
No visual guidance on standard units
Fibrosis, steatosis, imaging
630 Expert also offers SSM + ultrasound
Cost & Investment
Complete system
Complete system
All patient types
M, XL probes sold separately
Universal design
Per additional probe
2-year included
Contract required
On-site training
Certification program
Workflow & Efficiency
Complete examination
Including repositioning
Visual guidance helps
Blind technique
Auto-generated
Auto-generated
Standard format
Standard format
Visual confirmation
Must be precise
Patient Success
Guided acquisition; see studies
XL probe often used
Visual guidance
Limited positioning
Can identify and avoid
Cannot visualize
Guided positioning
May be challenging
Gentle approach
With care
FibroScan in high-BMI patients
A primary driver for clinics evaluating alternatives is the performance of traditional blind elastography in obese patients. Published literature indicates that the classic FibroScan M-probe can experience failure rates of 20–25% in cohorts with a BMI > 30.
While the FibroScan XL probe was developed to mitigate this by adjusting the focal depth, it requires purchasing and maintaining a second probe, and the operator is still acquiring measurements without visual confirmation of the liver parenchyma. Guided elastography addresses the root cause by allowing the clinician to see exactly where the shear wave is being generated.
Who should consider the guided alternative?
- 1New clinic setupsAvoid the $90k+ capital burden of legacy systems. Guided elastography offers a faster path to ROI.
- 2High-BMI cohortsIf your practice manages high volumes of MAFLD, obesity, or type 2 diabetes, 2D guidance is essential for reliable acquisition.
- 3Previous TE failuresClinics frustrated by high IQR ratios or the constant need to switch probes find immediate workflow relief with a universal guided probe.
- 4Primary care screeningWhen evaluating a patient with an indeterminate FIB-4 score, you need a reliable, cost-effective second-line test.
The Verdict
Guided elastography systems supplied through Elastography Australia offer the same core outputs as standard FibroScan workflows, plus real-time imaging guidance that can improve confidence—especially in challenging patients—often at approximately half the capital cost.
Common questions
Which is better — FibroScan or elastography?
FibroScan is a type of elastography (vibration-controlled transient elastography). The relevant comparison is between blind transient elastography (FibroScan standard models) and guided 2D shear wave elastography. Guided systems use real-time ultrasound imaging to position the probe, which improves success rates in obese patients and reduces operator dependency. Both measure liver stiffness in kPa.
Is elastography better than FibroScan?
FibroScan is itself an elastography device — it performs vibration-controlled transient elastography (VCTE). The question usually means: is guided 2D shear wave elastography better than blind VCTE? For patients with high BMI or narrow intercostal spaces, guided systems achieve higher acquisition success rates. For standard patients, both methods are clinically validated and guideline-supported.
Shear wave elastography vs FibroScan — what's the difference?
FibroScan uses vibration-controlled transient elastography (VCTE), which generates a single shear wave using an external vibrator. 2D shear wave elastography (2D-SWE), used by the iLivTouch system, uses acoustic radiation force impulse (ARFI) to generate shear waves while providing simultaneous B-mode imaging. 2D-SWE allows real-time visual guidance of the measurement, which VCTE does not. Both produce liver stiffness in kPa and are guideline-supported.
Further Reading
Mar 2026
FibroScan Alternatives in Australia: A Buyer's Guide to Liver Elastography
What Australian buyers evaluate when comparing transient elastography systems: guidance, workflow, obese-patient performance, probes, and total cost of ownership.
Mar 2026
Liver Scan in Obese Patients: Practical Considerations for Clinics
Operational guide to non-invasive liver assessment in higher-BMI cohorts, including workflow and acquisition considerations.
Apr 2026
FibroScan Limitations: What Australian Clinics Need to Know | Elastography Australia
FibroScan is the market-leading liver elastography device, but it has documented limitations in obese patients, workflow efficiency, and operator guidance. Here's what the evidence shows.